Latest Regulatory Milestones News

Lindian Resources reports steady progress at its Kangankunde Rare Earths Project in Malawi, maintaining schedule for first production in late 2026 with key infrastructure and regulatory milestones achieved.

Audalia Resources has secured $450,000 through a share placement to push forward mining design and regulatory approvals at its Medcalf Project.

Axel REE reports thick, shallow rare earth mineralisation with strong heavy rare earth enrichment at Woolrich, underpinning plans for an Indicated resource upgrade and in-situ recovery trials.

Sinowin Lithium, MRG Metals’ JV partner, commits to fund drilling at the Marão Titanium Dioxide Project in Mozambique, aiming to expand mineralisation and underpin a mining licence application amid broader JV progress.

Noxopharm is gearing up for a pivotal pre-IND meeting with the US FDA, enlisting global CRO Novotech to sharpen its regulatory approach for SOF-SKN, a drug targeting autoimmune skin diseases.

Patagonia Lithium has completed a key packer test at its Formentera project, confirming high aquifer porosity and flow rates at 110m depth, while submitting a comprehensive environmental study to local authorities.

NH3 Clean Energy’s WAH2 Clean Ammonia Project has been granted Federal Major Project Status, accelerating government approvals and supporting a Final Investment Decision by end 2026.

Ore Resources (ASX: OR3) has kicked off a 3,000m reverse circulation drilling campaign at its Coolgardie Lithium Projects, targeting strike extensions and infill at the Big Red and Potoroo pegmatites. The program follows strong historical lithium intercepts and promising metallurgical testwork, with results due in June 2026.

Following the granting of a 25-year mining permit, AKORA Resources has launched a $3.3 million capital raising to fund development and financing activities at its high-grade Bekisopa iron ore project in Madagascar.

Arovella Therapeutics undergoes a major board overhaul and CEO resignation following a shareholder push, as the company embarks on a strategic review of its cell therapy platform.

AdAlta has secured A$2.5 million in a strategic placement to push its lead CAR-T therapy BZDS1901 through critical US FDA regulatory steps and establish Australian manufacturing, building on promising clinical responses in advanced mesothelioma.

PYC Therapeutics presented Phase 1/2 data at ARVO 2026 showing encouraging safety and efficacy signals for its RNA therapies targeting rare genetic eye diseases Retinitis Pigmentosa type 11 and Autosomal Dominant Optic Atrophy.